Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bilh 434
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Bilh 434 is an experimental small molecule inhibitor targeting the human papillomavirus (HPV) E1/E2/DNA complex. It binds specifically to the transactivation domain (TAD) of the HPV E2 protein with high affinity (Kd = 40 nM), and inhibits formation of the E1-E2-ori complex with an IC50 of 180 nM[8]. The compound has a molecular formula of C29H19Cl2N3O6S and a molecular weight of approximately 608.45 g/mol[1][10]. Bilh 434 is not approved for clinical use in any country and has not advanced beyond preclinical or early experimental stages[1]. Its primary indication under investigation is as an antiviral agent against HPV infection.
- Other names
- DB04330DB-04330DB 04330CNP0499864.1CNP-0499864.1CNP 0499864.1
02
Targets
HPV-11 (Human papillomavirus type 11)
Beyond the preview
Go deeper on bilh 434.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bilh 434.